SCHEDULE 13G/A: BB Biotech AG Maintains Significant 15.8% Stake in MacroGenics Inc.
Beneficial Ownership Report
BB Biotech AG and its subsidiary Biotech Target N.V. have disclosed their continued beneficial ownership of 15.8% of MacroGenics Inc.'s common stock as of December 31, 2024.
Summary
- BB Biotech AG, a Swiss entity, and its wholly-owned subsidiary, Biotech Target N.V. (based in Curacao), have filed an Amendment No. 10 to Schedule 13G.
- The filing reports their beneficial ownership in MacroGenics Inc. (CUSIP: 556099109) Common Stock.
- As of December 31, 2024, the reporting persons collectively beneficially own 9,929,963 shares of MacroGenics Inc. common stock.
- This aggregate amount represents 15.8% of the class of securities.
- Both BB Biotech AG and Biotech Target N.V. hold shared voting power and shared dispositive power over all 9,929,963 shares.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of MacroGenics Inc.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing (Schedule 13G) disclosing beneficial ownership. It contains no subjective language, forward-looking statements, or performance metrics that would indicate a positive or negative sentiment. It is purely informational.
Future Outlook
NA
Industry Context
This filing is a standard regulatory disclosure by a significant institutional investor in the biotechnology sector, indicating a continued substantial stake in MacroGenics Inc. It reflects an investor's long-term position rather than a strategic industry shift or competitive analysis.
Related Party Transactions
- BB Biotech AG and its wholly-owned subsidiary, Biotech Target N.V., are filing jointly as related parties, with Biotech Target N.V. being the entity directly holding the securities.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's continued large stake in the company, which can influence market perception and stability.
Key Dates
| Date | Description |
|---|---|
| 2016-12-29 | Date of initial Schedule 13G filing by BB Biotech AG and Biotech Target N.V. (referenced for Exhibit A) |
| 2024-12-31 | Date of event which requires filing of this statement (ownership snapshot date) |
| 2025-02-12 | Date of filing and signature for this Amendment No. 10 to Schedule 13G |
Keywords
MacroGenics Inc, BB Biotech AG, Biotech Target N.V., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.